Bristol Myers Squibb Reports Q4 & Full-Year 2025 Results, Provides 2026 Revenue Decline Guidance
BMY sits 38% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb reported Q4 and full-year 2025 financial results, with flat full-year revenue and a 2026 revenue guidance projecting a decline. The company also announced a dividend increase and mixed pipeline updates.
Key Events · Earnings and Guidance · BMY
-
Q4 and Full-Year 2025 Financial Results
Fourth quarter revenues increased 1% to $12.5 billion, with full-year revenues at $48.2 billion, relatively flat compared to 2024. Non-GAAP diluted EPS was $1.26 for Q4 2025 (down 25% YoY) and $6.15 for the full year 2025 (up significantly from a low base in 2024).
-
2026 Financial Guidance Issued
The company provided 2026 guidance, projecting total revenues of approximately $46.0 billion to $47.5 billion, reflecting an anticipated 12-16% decline in the Legacy Portfolio. Non-GAAP diluted EPS is expected to be in the range of $6.05 to $6.35. Worldwide Eliquis revenue is expected to grow 10-15%.
-
Growth Portfolio Performance
The 'Growth Portfolio' revenues increased 16% in Q4 to $7.4 billion and 17% for the full year to $26.4 billion, driven by products like Opdivo, Yervoy, Reblozyl, Breyanzi, Opdualag, and Camzyos.
-
Pipeline Updates and Setbacks
Positive pipeline updates include Camzyos Phase 3 topline results and Opdivo receiving priority review for Hodgkin Lymphoma. However, the company, in collaboration with Johnson & Johnson, decided to stop the Phase 3 Librexia ACS trial for milvexian.
Analysis · BMY · Life Sciences
Bristol Myers Squibb's latest earnings report presents a mixed financial picture. While the company's 'Growth Portfolio' showed strong performance, the overall revenue for 2025 was flat, and the 2026 revenue guidance indicates a decline. This suggests ongoing challenges from the 'Legacy Portfolio' despite new product successes. The dividend increase is a positive signal of capital allocation, but the pipeline update includes a setback with the milvexian trial discontinuation. Investors will be closely watching the company's ability to offset legacy product declines with growth from newer assets and pipeline advancements, especially given the projected revenue contraction for the upcoming year.
At the time of this filing, BMY was trading at $58.70 on NYSE in the Life Sciences sector, with a market capitalization of approximately $117.3B. The 52-week trading range was $42.52 to $63.33. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.